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Abstract
Background: Morphine, the principal active agent in opium, is not restricted to plants, but is also present in different animal
tissues and cell types, including the mammalian brain. In fact, its biosynthetic pathway has been elucidated in a human
neural cell line. These data suggest a role for morphine in brain physiology (e.g., neurotransmission), but this hypothesis
remains a matter of debate. Recently, using the adrenal neuroendocrine chromaffin cell model, we have shown the
presence of morphine-6-glucuronide (M6G) in secretory granules and their secretion products, leading us to propose that
these endogenous alkaloids might represent new neuroendocrine factors. Here, we investigate the potential function of
endogenous alkaloids in the central nervous system.
Methodology and Principal Findings: Microscopy, molecular biology, electrophysiology, and proteomic tools were applied
to human neuroblastoma SH-SY5Y cells (i) to characterize morphine and M6G, and (ii) to demonstrate the presence of the
UDP-glucuronyltransferase 2B7 enzyme, which is responsible for the formation of M6G from morphine. We show that
morphine is secreted in response to nicotine stimulation via aC a
2+-dependent mechanism involving specific storage and
release mechanisms. We also show that morphine and M6G at concentrations as low as 10
210 M are able to evoke specific
naloxone-reversible membrane currents, indicating possible autocrine/paracrine regulation in SH-SY5Y cells. Microscopy
and proteomic approaches were employed to detect and quantify endogenous morphine in the mouse brain. Morphine is
present in the hippocampus, cortex, olfactory bulb, and cerebellum at concentration ranging from 1.45 to 7.5 pmol/g. In the
cerebellum, morphine immunoreactivity is localized to GABA basket cells and their termini, which form close contacts on
Purkinje cell bodies.
Conclusions/Significance: The presence of morphine in the brain and its localization in particular areas lead us to conclude
that it has a specific function in neuromodulation and/or neurotransmission. Furthermore, its presence in cerebellar basket
cell termini suggests that morphine has signaling functions in Purkinje cells that remain to be discovered.
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Introduction
Morphine is one of the 40 alkaloids present in opium from Papaver
somniferum, and is one of the strongest known analgesic compounds
[1]. Endogenous morphine has been characterized in numerous
mammalian cells and tissues [2,3,4], and its structure is identical to
that of morphine from poppy (for review see [1,5]). In mammals, the
biosynthesis of endogenous morphine is associated with that of
dopamine and catecholamines [5,6,7,8,9,10]. Morphine biosynthesis
was recently shown in the SH-SY5Y human neuronal catechol-
amine-producing cell line [8,9], a well-known model for studying
neuronal secretion [11,12]. Recently, our group has reported the
presence of morphine-6-glucuronide (M6G), previously considered a
product of morphine catabolism, in the secretory granules and
secreted material of bovine adrenal chromaffin cells. In these cells,
M6Grepresentsthefinalproductofendogenousalkaloidbiosynthesis
and is formed through the action of an UDP-glucuronosyltransferase
2B-like enzyme (UGT2B). In chromaffin granules, M6G is bound to
the intragranular phosphatidylethanolamine-binding protein (PEBP
or Raf kinase inhibitor protein) [13], which also binds morphine [14].
Secretion of M6G, catecholamines, and PEBP [15] into the blood is
likely to occur during stresssituations,and could be involved in differ-
ent stress-modulating or pain-modulating mechanisms via binding to
mopioid receptors (MORs), which arepresent on numerous cell types
[16,17,18]. Together, all these observations suggest that endogenous
alkaloids may represent new neuroendocrine factors [15].
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rats, monkeys, and dogs (for review, see [1]). However, the function
of endogenous morphine in the brain remains unknown, and
knowledge of its distribution in cerebral areas and neuronal cells is
lacking. Enzymes such as those in the UGT1A family, implicated in
converting morphine to inactive M3G, are expressed in rat primary
neurons and astrocytes [19]. UGT2B7, which produces M6G and
M3G, is also expressed in the human brain [20]. Interestingly,
human and rat brain extracts incubated with radiolabeled morphine
produce labeled M3G and M6G [21,22]. Nevertheless, it remains a
matter of debate whether morphine or its derivatives function as
neuromediators and/or neurotransmitters.
Thepresentstudyaddressesthefunctionofmorphineinthebrain.
Microscopy, biochemistry, cell biology, molecular biology, and
electrophysiology have been used to characterize morphine and its
derivatives in detail in the human SH-SY5Y neuroblastoma cell
model. At the ultrastructural level, morphine immunoreactivity
colocalizes with that of chromogranin A (CGA), a well-known
marker of Large Dense Core (LDC) vesicles. We have found that the
UGT2B7enzyme,whichconvertsmorphinetoM6G,isexpressedin
these cells. Upon nicotine stimulation, morphine is released from
SH-SY5Ycellsvia aC a
2+-dependent mechanism.Experimentsusing
the patch-clamp technique reveal that naloxone-sensitive electro-
physiological responses are induced at concentration of morphine
and M6G as low as 10
210 M. To extend these experiments in
cultured cells, we quantified morphine levels in different areas of the
mouse brain. In the cerebellum, morphine immunoreactivity is
concentrated in the basket cells and their termini, which innervate
Purkinjecellbodies. This study documentsthe presence ofmorphine
in the brain and shows a specific localization that implies a signaling
role that is yet to be precisely established.
Results
Human neuroblastoma SH-SY5Y cells synthesize endogenous
morphine [9] and express MORs [17,23,24]. Therefore, we used
this cell line to determine the subcellular localization, biosynthesis,
and secretion of morphine.
Subcellular localization of morphine in SH-SY5Y cells
Using laser confocal microcopy, the labeling obtained with an
anti-morphine sheep polyclonal antibody was compared to that of
CGA [15], a specific marker of LDC vesicles [25,26,27,28]. Anti-
morphine immunolabeling showed a punctate pattern in the
cytoplasm, similar to that obtained with the anti-CGA antibody
(Fig. 1A). Superimposition of the two labelings reveals an
intravesicular colocalization (Fig. 1A, yellow label). At higher
magnification, anti-morphine immunolabeling was also visible in
neurite termini, and remained clearly colocalized with CGA
(Fig. 1A, lower panel, arrows). Control experiments established the
specificity of the labeling in vesicles using either the secondary
antibody alone, non-immune sheep serum (Fig. 1B), or the anti-
morphine antibody blocked with morphine prior to its use in
immunocytochemistry experiments [15].
Evidence for the presence of UGT2B7 in SH-SY5Y cells
The next step was to examine whether SH-SY5Y cells have the
capacity to synthesize M6G. First, a PCR approach was used to
determine whether UGT2B7, the only enzyme known to convert
morphine into M6G, is expressed in SH-SY5Y cells. As shown in
Figure 2A, amplification of UGT2B7 RNA performed on SH-
SY5Y total RNA extracts indicates the presence of a single band at
462 bp, which corresponds to the band present in total RNA from
human primary hepatocytes.
These experiments were then complemented by Western blot
analysis of SH-SY5Y cell extracts in order to detect UGT2B
protein expression (Fig. 2A). Using recombinant human UGT2B7
as a positive control (Fig. 2A), UGT2B-like immunoreactivity was
observed as a band at 65 kDa, showing, for the first time, that SH-
SY5Y cells may be capable of synthesizing M6G.
The subcellular localization of the UGT2B7 enzyme was
examined by laser confocal immunocytochemistry and compared
to that of morphine and CGA. The punctuate labelling of UGT2B
overlapped with that of morphine (Fig. 2B, yellow label), revealing
the presence of UGT2B in LDC vesicles. These results indicate
that the M6G-producing enzyme UGT2B7 is expressed in SH-
SY5Y cells, and that it colocalizes with morphine.
Characterization of morphine and M6G in SH-SY5Y cells
After showing that the UGT2B-like enzyme is present in SH-
SY5Y cells, we sought to confirm the presence of morphine and
M6G in the cells using mass spectrometry (MS). SH-SY5Y extracts
were purified by HPLC (high performance liquid chromatography)
using a specific gradient designed to separate morphine and M6G.
Comparison with an elution profile of alkaloid standards (Fig. 3A)
allowed for the identification of fractions containing endogenous
morphine and M6G.Q-TOF MS-MS analysis of material present in
the corresponding fractions unambiguously identified both mor-
phine (m/z=286.13Da; Fig. 3C) and M6G (m/z=462.15Da;
Fig. 3B). Together, these data confirm the presence not only of
endogenous morphine, but also of M6G in SH-SY5Y cells.
Morphine secretion from SH-SY5Y cells
In order to quantify morphine secretion from SH-SY5Y cells and
to determine whether it occurs via aC a
2+-dependent mechanism,
cells were stimulated with 100 mM nicotine to trigger membrane
depolarization and LDC vesicle exocytosis [28]. The amount of
morphinereleasedwasmeasuredusingaspecificandsensitiveELISA
technique. A low basal level of morphine secretion was observed in
the absence of nicotine (Fig. 4). Stimulation of SH-SY5Y cells with
100 mM nicotine induced a five-fold increase in secreted morphine
overbackground (Fig.4). In the presence of the Ca
2+-channel blocker
cadmium, basal secretion remained unchanged, while nicotine-
induced secretion of morphine decreased dramatically. These results
unambiguously indicate that morphine can be released via aC a
2+-
dependent mechanism upon stimulation of SH-SY5Y cells.
In order to identify the origin of stored morphine, the release of
chromogranin B (CGB), an intragranular marker of SH-SY5Y LDC
vesicles [28], was investigated by Western blot analysis (Fig. 4). The
presence of an 80 kDa CGB-immunoreactive band was detectable
among proteins in the extracellular medium when cells were treated
with nicotine. Similar to morphine, nicotine-evoked CGB secretion
also dramatically decreased when cadmium was present in the
medium (Fig. 4). In conclusion, SH-SY5Y cells secrete morphine via
aC a
2+-dependent mechanism in response to nicotine stimulation.
Evidence for physiological effects of morphine and M6G
on SH-SY5Y cells
To address whether morphine and M6G induce a physiological
response in SH-SY5Y cells, we first looked at the expression of the
m opioid receptor family (MOR1; [17,18,29,30]). Using SH-SY5Y
total RNA library, we detected MOR1 transcripts using PCR
(Fig. 5A, 376 bp band), suggesting that SH-SY5Y cells are
responsive to morphine or M6G.
In light of these results, we examined the response of SH-SY5Y
cells to alkaloids using the patch clamp electrophysiological
approach. As shown in Figure 5, SH-SY5Y cells were responsive
Morphine in Brain Cells
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configuration. Approximately 70% of the 26 randomly chosen
cells were responsive.
The cellular response to M6G application was fully reproducible
inabout80%ofpositivecells(Fig.5C).However,20%ofthepositive
cells responded to a first M6G application, but not to subsequent
applications even after one hour of washout, suggesting a strong
desensitization in these cells. M6G was active in SH-SY5Y cells at
doses as low as 0.1 nM M6G (Fig. 5D). The cellular response in
whole-cell recording corresponded to a membrane potential of
280 mV and an inward current, the peak amplitude of which was
dose-dependent. Dose-response curves were obtained for 13
different cells tested with M6G at concentrations ranging from 0.1
to 100 nM. The peak amplitude cellular response was normalized to
the cell surface area in order to reduce variability due to cell size.
Application of Hill’s model to the dose-response data yielded an
ED50valueof2.1 nMandaslopeof0.6(Fig.5D,middlepanel).The
I-V plot obtained at the peak cellular response to 0.1 nM M6G was
linear. Linear regression analysis of the specific current data in the
presence of M6G yielded a calculated reversal potential of about
20.5 mV (Fig. 5D, right-hand panel, upright triangles). This value
was close to the equilibrium potential (Ecat=0 mV) for monovalent
cations, indicating that M6G activates a channel that allows for the
passage of Na and K ions. Figure 5C illustrates the sensitivity of the
M6G response to the opioid receptor antagonist naloxone. When
used at a concentration of 2.5 mM, naloxone inhibited 90% of the
cellular response to 0.1 mM M6G. Morphine produced similar
effects when applied at low concentration (Fig. 5B).
These data indicate that morphine and M6G can evoke specific
membrane currents at low concentrations via opioid receptors,
indicating a possible regulatory role for secreted morphine/M6G
in SH-SY5Y cell culture.
Immunomapping of endogenous morphine in the
mouse brain
The presence in SH-SY5Y cells of endogenous alkaloids in LDC
vesicle-like structures, their release by a Ca
2+-dependent exocy-
totic mechanism, and their effects on these cells at concentration as
low as 0.1 nM led us to investigate whether endogenous morphine
may represent a neuromodulator in the mouse brain, where M6G
is absent [31].
The localization of endogenous morphine was examined in the
mouse CNS by immunocytochemistry using an anti-morphine
mouse monoclonal antibody (6D6 antibody). Light microscopy
Figure 1. Evidence of the presence of morphine-like immunoreactivity in secretory granules. A. Upper panel,d o u b l e
immunofluorescence confocal micrographs. Labeling was performed with a sheep anti-morphine antibody (visualized in green with an Alexa
Fluor 488-conjugated IgG) and with an antibody against CGA (a specific intragranular marker) visualized in red with a mouse Cy3-conjugated IgG.
Colocalized immunolabelling (merged window) appears as yellow staining. Lower panel, SH-SY5Y termini shown at higher magnification. Arrows
indicate colocalization points. An identical pattern of labelling was obtained for a different mouse monoclonal anti-morphine antibody (data not
shown). B. To assess the specificity of morphine immunolabelling, control experiments were performed using either sheep non-immune serum and
an Alexa Fluor 488-conjugated IgG, or Alexa Fluor 488-conjugated IgG and Cy3-conjugated IgG without a primary antibody.
doi:10.1371/journal.pone.0001641.g001
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defined brain structures such as the cerebellum, the olfactory bulb,
the hippocampus, and the cortex (Fig. 6A). Fainter, dispersed
labelling was seen in other structures. Quantification of morphine
levels in these areas was performed using a morphine-specific
ELISA kit. The higher amount of morphine (7.46 pmol/g of fresh
tissue) was present in the hippocampus (Fig. 6C; n=5). We chose
to focus on the cerebellum area in greater detail because of the
apparently clear-cut Purkinje cell labelling (Fig. 6A) and the
concomitant presence of MORs in these cells [32,33]. Conven-
tional microscopy, however, revealed that the labelling was not
within Purkinje cells themselves, but rather in synaptic endings in
contact with Purkinje cells (Fig. 6D, PC). Immunolabelling was
observed in basket cells close to Purkinje cells (Fig. 6D, BC). In
addition, discrete morphine immunolabelling could be observed in
the white matter afferent fibers and in some isolated cells (data not
shown). Synapses innervating the Purkinje cell bodies originate
from basket cells known as inhibitory GABA interneurons, which
are located in the molecular layer close to the Purkinje cells.
Electron and laser confocal microscopy were used to determine
whether labelling was present in basket cells:
(i) Electron microscopy experiments showed strong immunola-
belling of nerve termini over the entire Purkinje cell body (Fig. 7A
& 7B). These endings originate from basket cells which were
immunoreactive to the morphine antibody (Fig. 7C).
In parallel, the immunoreactivity of the morphine-binding
protein PEBP [14] was found in basket cell nerve termini around
Purkinje cell bodies (Fig. 7D, arrow), suggesting the presence of a
morphine-PEBP complex in these structures.
(ii) Confocal microscopy experiments using both anti-morphine
and anti-glutamic acid decarboxylase antibodies revealed the
colocalization of morphine and glutamic acid decarboxylase
around the Purkinje cell bodies (Fig. 7E, yellow label on the
merge window). Appropriate controls confirmed the specificity of
this immunolabelling (Fig. 7F).
Discussion
The significance of the detection of endogenous morphine in the
brains of rats, mice, monkeys, and cows remains a matter of debate
as long as its functional role is unknown [1,34]. Previous studies
have shown that radiolabelled morphine is taken up and secreted
by brain slices and immune cells [22,35,36,37]. Further study has
linked levels of endogenous morphine in the brain to physiological
states (e.g., inflammation and fasting) [7,38,39,40]. However, a
thorough investigation to determine whether endogenous mor-
phine acts as a true neuromodulator has not yet been published.
Figure 2. Evidence for UGT2B7 in SH-SY5Y cells. A. Amplification of UGT2B7 RNA and Western blot analysis. Left panel, total SH-SY5Y RNA was
submitted to RT-PCR using specific human UGT2B7 primers. Lane 1, control using water to test for contamination. Lane 2, total RNA from human
hepatocyte extract was used as a positive control, showing a single band of 462 bp corresponding to the expected UGT2B7 PCR product. Lane 3, SH-
SY5Y total RNA showing a single band of 462 bp. Lane 4, negative control of GAPDH amplification (water). Lane 5, SH-SY5Y total RNA (GAPDH,
142 bp). The size of standards are indicated in bp. Right panel, Western blot analysis of SH-SY5Y cell extracts was done using 1 mg of human
recombinant UGT2B7 (positive control) and 50 mg of SH-SY5Y cell extract. Western blots using anti-UGT2B antibody show a band at 65 kDa [15]. B.
Localization of UGT2B immunoreactivity in SH-SY5Y cells. Double immunofluorescence confocal micrographs were obtained using an anti-UGT2B
antibody (detected in red with an Alexa Fluor 568-conjugated IgG) and with an antibody against morphine visualized in green with an Alexa Fluor
488-conjugated IgG. Colocalized immunolabelling appears as yellow staining (merged window).
doi:10.1371/journal.pone.0001641.g002
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PLoS ONE | www.plosone.org 4 February 2008 | Volume 3 | Issue 2 | e1641The aim of the present study was to begin to examine this question
and thereby take the first steps towards establishing a functional
role for endogenous morphine.
To be considered a neurotransmitter, endogenous morphine
should (i) be present in nerve terminals and stored within secretory
vesicles, (ii) possess a specific pre/postsynaptic receptor able to
induce specific effects (i.e., MOR), (iii) be released upon
depolarizing stimulation via aC a
2+-dependent mechanism, and
(iv) be degraded or recycled by an extra- or intracellular
mechanism. We examined these criteria using the neuronal SH-
SY5Y cell line and mouse brain.
(i) Presence of morphine in secretory granules and nerve
termini
The human neuroblastoma clone SH-SY5Y, derived from a
human sympathetic ganglion [41], possesses the properties of
sympathetic neurons [42] and is a well-established model for
studying the secretion of neurotransmitters [11,12,28]. These cells
have been shown to express several types of receptors, including
MOR and d opioid receptor subtypes (DOR) [16,17,18]. SH-
SY5Y cells are characterized by the presence of numerous LDC
vesicles (100–200 nm in diameter) which are usually found in
sympathetic neurons and that closely resemble the adrenal
chromaffin secretory granules. These LDC vesicles store neuro-
transmitters such as noradrenaline, enkephalins, and chromogra-
nins. Morphine synthesis has been observed in SH-SY5Y cells [9].
The present results reveal that morphine immunoreactivity (which
identifies morphine and M6G) is present within secretory
structures, as shown by its colocalization with CGA. The
colocalization in LDC vesicle-like structures occurs in cell bodies
but also along cell processes and within neurite endings.
Biochemical analyses using the sensitive technique of mass
spectrometry confirmed the presence not only of morphine in SH-
SY5Y cell extracts, but also of M6G, a product of morphine
catabolism that has never been found in this cell type [43,44]. We
recently reported the presence of M6G in the matrix of bovine
adrenal chromaffin secretory granules, as well as in the material
secreted from chromaffin cells [15]. We were able to show that in
chromaffin cells, M6G is a product of anabolic synthesis by UDP-
glucuronosyltransferase 2B-like enzyme (UGT2B). However, the
UGT2B7 detected here in SH-SY5Y cells is probably responsible
for M6G biosynthesis. While in chromaffin cells morphine is
almost completely metabolized into M6G, we found that
morphine and M6G coexist in SH-SY5Y cells, suggesting that
the two molecules are cosecreted in vivo.
Using an immunohistochemical approach, morphine was detect-
able in the mouse CNS, particularly in specific neurons and nerve
terminals. A strong localized immunoreactivity was observed in the
cerebellum, olfactory bulb, hippocampus, and cortex, whereas other
structures showed more dispersed labelling. Faint immunolabelling
was also visible in the white matter, and this may correspond to
morphine-positive afferent fibers. Using optical methods, we
observed intense immunostaining in the cerebellum surrounding
Purkinje cell bodies and in basket cells. Ultrastuctural techniques
showed morphine immunoreactivity to be concentrated in the cell
bodies of basket cells and their endings that make close contacts with
Purkinje cell bodies. These anatomical findings implicate this
endogenous alkaloid in cerebellum activity.
(ii) Presence of a specific pre/postsynaptic receptor
We investigated whether SH-SY5Y cells respond to the
application of morphine and M6G. First, we confirmed that they
Figure 3. Characterization of morphine and M6G in SH-SY5Y extracts. A. Purification of morphine and M6G. Upper panel, RP-HPLC
chromatogram showing the purification of endogenous alkaloids from SH-SY5Y cells (375610
6 cells). Lower panel, RP-HPLC purification of morphine
(Mor) and M6G standards (500 pmol). B. Characterization of M6G. Q-TOF MS-MS analysis of the HPLC fraction showing M6G in the intragranular
material (marked with an arrow in Fig. 3A, upper panel). The fragment at 462.12 Da corresponds to M6G, whereas the 286.18 Da fragment
corresponds to morphine. C. Q-TOF MS analysis of the HPLC fraction showing morphine (286.17 Da) in the intragranular material (marked with an
arrow in Fig. 3A, upper panel).
doi:10.1371/journal.pone.0001641.g003
Morphine in Brain Cells
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receptor proteins derived from the OPRM (opioid receptor m)g e n e .
MORs are membrane proteins with seven transmembrane domains,
and they are coupled to Go/i proteins (for review, see [45]).
Stimulation of these receptors leads to various effects, including
analgesia and regulation of the gastrointestinal tract. The distribu-
tion of MORs in the mouse brain has previously been investigated
using immunohistochemistry and molecular biology [46]. However,
this is a complex problem given the multiplicity of splice variants,
with 32 mRNA splice forms and at least 11 receptor isoforms for
mouse MOR1 [1,45,47]. MOR1 subtypes have been described in
mouse, rat, and cat Purkinje cells [32,33,48,49].
The presence of morphine in cerebellum basket cells that form
synaptic contacts with Purkinje cell bodies led us to speculate that
endogenous morphine may be involved in modulating Purkinje
cell output. It is well known that GABA liberated from basket cell
endings modulates Purkinje cell activity. Moreover, DAMGO and
baclofen, two MOR agonists, have been reported to regulate non-
activating outward currents in mouse Purkinje cells when used at
mM concentrations [50]. Interestingly, DAMGO inhibits GABA
neurotransmission [51]. In the case of morphine, microiontopho-
retic application to cat Purkinje cells induces either excitatory or
inhibitory responses (i.e., an increase or decrease of the firing rates,
respectively) [48,49]. Naloxone reverses excitatory morphine-
evoked actions, whereas inhibitory effects can be reversed only by
the GABA-receptor antagonist bicuculine. This suggests that the
excitation of cat Purkinje cells by morphine is related to MORs,
whereas inhibitory events involve GABA receptors. Whether
morphine and GABA are stored in the same vesicles and released
together from basket cells remains an open question. The presence
of both molecules in the nerve endings of the same cell may imply
complex regulatory processes yet to be elucidated.
(iii) Secreted morphine
At least 11 mouse MOR1 isoforms exist [47] and have various
affinities for morphine and its derivatives (Kis ranging from
nanomolar to low affinity for the mMOR-1B4 isoform [45,52]),
which means that specific morphine concentrations are needed to
activate a given receptor isoform. In addition, homo- and hetero-
dimerisation of MOR1 subtypes (or DOR) induce switch in
signaling [53].
Endogenous morphine may play a role in brain plasticity and
development. At very low concentration (10
29 to 10
214 M),
morphine increases neurite outgrowth in rat primary neuron cultures
[54], as well as in the PC-12 tumor cell line [55], via an a l o x o n e -
independent pathway. In addition, MORs are involved in granule
neuron genesis in the mouse cerebellum [56]. Recently, Zeng et al.
demonstrated that morphine promotes the regeneration and synaptic
reconstruction of the terminals of injured primary unmyelinated
afferent fibers by an MOR-mediated, naloxone-dependent process
[57]. Morphine has also beenshown tomodulatesynaptic plasticity at
hippocampal glutamatergic synapses [58]. Together, these data
suggest that secreted endogenous morphine, at low concentrations,
can act as a neurofactor involved in regulating the development of
specific brain areas or in neuronal plasticity. Morphine activity at low
concentrations was also observed in the present study, since the
electrophysiological responseof SH-SY5Y cells occurred at morphine
and M6G concentrations as low as 10
210 M.
Previous reports have shown that PEBP is able to bind
morphine [14] and M6G [15], suggesting that PEBP is an
endogenous morphine/M6G binding protein. In the present
study, PEBP immunoreactivity colocalized with that of morphine
in basket cell nerve endings, which suggests the presence of PEBP-
morphine complexes. Whether morphine is secreted in a complex
with PEBP remains an open question.
(iv) Presence of a specific catabolism process for
morphine
Neurotransmitters are commonly inactivated in the synaptic
gap by enzymes [59], or they are taken up by neurons and
astrocytes for recycling or degradation [60]. Once inactivated
inside the cell, the inactive product is released into the extracellular
space. If morphine is a true neurotransmitter, it should be either
inactivated or recycled.
Figure 4. Characterization of morphine secretion from SH-
SY5Y cells. Upper panel. The amount of morphine secreted into the
culture medium was determined after stimulating 4610
5 cells with
100 mM of nicotine with or without cadmium (200 mM) for 24 h. The
basal secretion level was obtained from cells incubated without
nicotine at the same time (n=6). Amounts of secreted morphine in
the nicotine and nicotine+cadmium groups were statistically different
and were both different from the two control groups (no nicotine and
no nicotine+cadmium; Mann-Whitney test, * p,0.01). Lower panel. The
efficiency of secretion was assessed by monitoring the secretion of
chromogranin B (CGB), an intra-LDC vesicle protein [28], by Western
blot analysis. A positive control, intragranular protein matrix from
bovine chromaffin cells (10 mg), was loaded in order to evaluate the
molecular weight of the entire CGB (80 kDa).
doi:10.1371/journal.pone.0001641.g004
Morphine in Brain Cells
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and M6G. A. Total SH-SY5Y RNA was submitted to RT-PCR using specific human MOR1 primers. Lane 1, control using water as a PCR template to test
for contamination. Lane 2, total RNA from SH-SY5Y, showing a single band of 376 bp. Lane 3, negative control of GAPDH amplification (water). Lane
4, SH-SY5Y total RNA (GAPDH, 142 bp). Size standards are indicated in bp. B and C. Typical responses of SH-SY5Y cells to low concentrations of
morphine and M6G antagonized by naloxone, as measured by the patch clamp technique in cell-attached mode at a pipette potential of 60 mV and
80 mV (B panel), as well as at 2135 mV (C panel). M6G was repeatedly applied in the absence or presence of naloxone (Nal.). D. Whole-cell patch
clamp recording of the M6G response: the left-hand panel shows a typical trace recorded at a holding potential of 2135 mV, the middle panel shows
a dose-response curve obtained at a holding potential of 280 mV, and the right-hand panel shows an I-V plot of the peak amplitude response. The
dose-response data were fitted with Hill’s equation (continuous line) with optimal parameters as indicated in the Figure. The I-V plot of the steady
state current for the control (circles) and at the peak of the response to 0.1 nM M6G (inverted triangles) was obtained using a ramp potential protocol
from 80 to 2140 mV lasting 800 ms. The specific current elicited in the presence of M6G (upright triangles) was linear, and the reversal potential
calculated by linear regression gave a value of 20.5 mV (dashed line). Traces were filtered at 2 kHz and digitized at 5 kH. Bars indicate the period of
drug application at the indicated concentrations.
doi:10.1371/journal.pone.0001641.g005
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in hepatocytes by enzymes of the UDP-glucuronosyl transferase
1A and 2B families (UGT) [61]. This leads to the formation of
morphine-3-glucuronide (M3G; 90%) and M6G (10%). In
contrast to the inactive M3G, M6G displays analgesic activity
that is much more potent than morphine [15,16]. In the rodent
liver, the picture appears to be more complex because in rats,
morphine is catabolized to both M6G and M3G [21], whereas
only M3G is formed in mice [31].
In the brain, morphine uptake has been described in different
cell types, including neurons [35]. Morphine is known to pass the
blood brain barrier and to penetrate into the CNS more actively
than M6G, probably because it is more hydrophilic [62]. Uptake
mechanisms for morphine also appear to exist in non-neuronal
cells, as shown by studies with radioactive morphine and human
primary white blood cells [22,35,36,37].
Interestingly, enzymes implicated in converting morphine into
M3G (i.e., UGT1A enzymes) are expressed in primary neurons [19]
and astrocytes [63]. Human and rat brain extracts, including those
from the cerebellum, are able to synthesize labeled M3G and M6G
from radiolabelled morphine [21,22], proving that morphine
catabolism/anabolism occurs in at least some brain structures. The
uptake of released morphine may occur at the pre- or postsynaptic
level in neurons as well as in astrocytes. Following uptake, morphine
may be recycled in secretory organelles or converted into M3G by
the UGT enzyme family present in neurons [64,65] and astrocytes
[63]. The resulting inactive M3G may then be transported from the
cytoplasm into the extracellular space [31].
Conclusion
Our present observations, together with previously published
data, strengthen the proposal that endogenous morphine repre-
sents a new neurotransmitter or neuromodulator involved in
signalling regulation. Further investigation is required to under-
stand the precise role of endogenous morphine in brain
physiology.
Figure 6. Mapping of endogenous morphine in the mouse brain. A. Immunodetection of morphine present in the mouse brain. Sagittal slices
were incubated with a mouse monoclonal anti-morphine antibody and visualized with an HRP-conjugated donkey anti-mouse IgG, in order to detect
endogenous morphine in specific brain areas. B. Control experiment using morphine immunoadsorbed mouse monoclonal antibody (same
incubation time as in A). C. Quantification of the morphine present in different mouse brain areas using morphine-specific ELISA. The table shows the
quantities of endogenous morphine (pmoles) present per gram of wet tissue. The values correspond to an average of the morphine amount
determined for 5 brains (n=5). D. Localization of morphine label in the cerebellum using mouse monoclonal anti-morphine antibody and an HRP-
conjugated secondary antibody. Morphine labelling was observed around Purkinje cells and in basket cells. PC, Purkinje cell; BC, basket cell. E. Control
for immunolabelling using morphine-immunoadsorbed mouse monoclonal antibody.
doi:10.1371/journal.pone.0001641.g006
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Animals
Experiments were performed on 37 day old laboratory-bred,
adult male C57BL/6 mice weighing 3063 g. Animals were given
free access to food and water, with a 12 h light-dark cycle at a
temperature of 2262uC. All experiments were carried out in
accordance with the European Community Council Directive
(86/609/EEC) of November 24, 1986.
Cell culture
The human SH-SY5Y cell line (ATCC number CRL-2266) was
cultured for 5 days in 60 cm
2 dishes in Dulbecco’s Modified Eagle
Figure 7. Characterization of morphine immunoreactivity in the mouse cerebellum. A. Characterization of morphine immunolabelling
around Purkinje cells. Electron microscopy using sheep anti-morphine antibody showed morphine-like immunoreactivity in nerve termini innervating
Purkinje cell bodies (PC). Arrows indicate strong immunolabelling of morphine-containing termini around the Purkinje cell body. GC, granular cell.
ML, molecular layer, N, nucleus. B. Higher magnification showing the presence of morphine immunoreactivity in nerve termini innervating Purkinje
cell bodies. C. Electron microscopy showing morphine immunoreactivity in basket cells (BC). BV, blood vessel. ML, molecular layer. Control
experiments using anti-sheep HRP-conjugated IgG showed the specificity of the immunolabelling. D. Electron microscopy showing PEBP-
immunoreactivity in nerve termini covering Purkinje cell bodies (PC). Arrows indicate strong immunolabelling of PEBP-containing basket cell termini.
E. Evidence of colocalization of morphine and glutamic acid decarboxylase (GAD). Double immunofluorescence confocal micrographs were obtained
using a sheep anti-morphine antibody (detected with a CY5-conjugated IgG, green pseudocolor label) and an antibody against GAD visualized in red
with a Cy3-conjugated IgG. Colocalized immunolabelling (arrows and merged window) appears as yellow staining. F. Control experiments were
performed using sheep non-immune serum, or only secondary antibodies detected with Cy5- and Cy3-conjugated IgG (primary antibody omitted), to
demonstrate the specificity of the immunolabelling.
doi:10.1371/journal.pone.0001641.g007
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bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
The cells were incubated at 37uC in a wet atmosphere (relative
humidity .95%) of 5% CO2 in air. The medium was changed
every three days.
Immunohistochemistry
Tissue preparation for immunocytochemistry studies.
Mice were deeply anesthetized by intraperitoneal injection of
0.1 ml of a 5.6% (w/v) pentobarbital sodium solution (CEVA
Sante ´ Animale) and perfused transcardially with fixative solution
using a peristaltic pump. For electron microscopy experiments, the
fixative solution consisted of 4% formaldehyde (Sigma-Aldrich) in
NaCl/Pi buffer (0.9%NaCland25 mMsodiumphosphate,pH 7.4)
with 0.25% glutaraldehyde (VWR). The same fixative solution was
used for optical microscopy, except that glutaraldehyde was omitted.
Fixative solutions were chilled, then injected for 10 min with a
peristaltic pump at a flow rate of 10 ml/min. The brain was quickly
removed and incubated for 2 hours at 4uC in the same fixative.
Coronal and sagittal brain sections (80 mm thick) were cut with a
vibratome (Leica VT 1000 S) and collected in Tris-buffered saline
(TBS: 50 mM Tris-HCl, 0.9% NaCl, pH 7.4).
Cell preparation for immunocytochemistry studies. Cells
cultured on glass coverslips were pre-fixed for 5 min with a solution
of 4% (v:v) formaldehyde in NaCl/Pi buffer mixed with the culture
medium at 25uC. Then, cells were fixed with 4% formaldehyde
solution in NaCl/Pi buffer and permeabilized for 10 min with 0.1%
(v/v) Triton X100 [15]. Glass coverslips were mounted on a glass
slide with a drop of Mowiol 4-88.
Immunostaining. Immunostaining was performed on
sections free-floating in TBS or on cells grown on coverslips as
previously described [66]. Sections or slides were washed in TBS
and incubated for 1 hour in bovine serum albumin diluted in TBS
(3%, w/v) in order to saturate nonspecific immunoreactive sites.
After six TBS washes of 5 min each, sections were incubated
overnight in different antisera. Primary antibodies were used as
follows: (i) mouse monoclonal antibodies (6D6, Aviva System
Biology; dilution 1:2000) or sheep polyclonal antibodies (AbD
Serotec; dilution 1:500) raised against morphine-like compounds
(morphine, M3G, and M6G, based on supplier specifications and
our own experiments, described below), (ii) goat polyclonal
antibody raised against human and murine UGT2B [15], (iii)
mouse monoclonal anti-glutamic acid decarboxylase (Chemicon;
dilution 1:1000), (iv) purified rabbit anti-PEBP antibody (dilution
1:100) [13] and (v) mouse monoclonal antibody anti-CGA 5A8
(dilution 1:500) [67].
After incubation with the primary antibody, sections or slides
were washed six times with TBS (5 min) and specific secondary
antisera were added for 2 h at room temperature, followed by six
TBS washes (5 min). These secondary antisera were (i) HRP-
conjugated donkey anti-mouse IgG (P.A.R.I.S.; dilution 1:500), (ii)
Alexa Fluor 488-conjugated donkey anti-sheep IgG (Molecular
Probes; dilution 1:2000), (iii) Alexa Fluor 568-conjugated donkey
anti-goat (1:2000), (iv) Cy5-conjugated donkey anti-sheep IgG
(Jackson Immunoresearch Laboratories; dilution 1:200) and (v)
Cy3-conjugated donkey anti-mouse IgG (Jackson Immunore-
search Laboratories, dilution 1:800).
Several controls were carried out to assess antibody specificity
and nonspecific immunoreactivity. Primary antibodies were
omitted, and each secondary antibody was tested individually or
in a mixture in the presence of tissue sections or cells. Controls for
morphine and UGT2B immunoreactivities were carried out by
incubating the antibody with morphine (2 h, 25uC, 50:1, w/w) or
the corresponding blocking peptide (12 h, 4uC, 1:5, w/w) [15],
respectively, prior to immunocytochemistry experiments. Each
antibody was also tested with the secondary antibody used for the
second immunolabelling in order to determine whether interspe-
cies cross-reactivity exists. Anti-morphine antibodies were also
tested by ELISA in order to determine cross reactivity with
morphine, M6G, and M3G, showing a specificity for morphine
M6G and M3G. In order to assess whether morphine binds to
proteins nonspecifically, extracts of SH-SY5Y and the mouse
hippocampus were submitted to Western blot analysis; the results
show that neither anti-morphine antibody labels proteins in these
extracts. All experiments using anti-morphine antibodies were
done in duplicate using mouse monoclonal and sheep polyclonal
antibodies. The pattern of immunolabelling was similar each time.
Light microscopy immunocytochemistry
Peroxidase activity was measured after a 20 min incubation in a
freshly prepared solution of 4-chloro 1-naphtol (0.2 mg/ml) in
TBS containing 0.006% (w/v) hydrogen peroxide. After washing
with TBS, the sections were mounted in glycerol/TBS (1:1, v/v)
before analysis with a Leica DMRB microscope equipped with a
digital camera (Axiocam, Zeiss).
Electron microscopy immunocytochemistry
Peroxidase activity was detected with a freshly prepared solution
of 0.025% (w/v) 3,3-diaminobenzidine tetrahydrochloride in TBS
containing 0.006% (w/v) hydrogen peroxide. After washing with
NaCl/Pi buffer, sections and slides were postfixed for 30 min with
2.5% glutaraldehyde in 0.1 M NaCl/Pi buffer (pH 7.4), and then
with 1% (w/v) osmium tetroxide in 0.1 M NaCl/Pi buffer
(pH 7.4) at 4uC for 1 hour. Sections were dehydrated in ethanol
and embedded in Araldite resin [66]. Ultrathin sections were
observed with a Hitachi H 7500 electron microscope without
additional staining. Pictures were acquired with a Hamamatsu
Digital camera (C 4742-95).
Confocal microscopy observations
Immunofluorescent staining was analyzed with a Leica laser
scanning microscope (TCS-SP2 invert) equipped with a plan apo
636oil immersion lens. Tissue sections were subjected to optical
serial sectioning to produce images in the X–Y plane. Each optical
section was scanned eight times for brain sections and four times
for cells to obtain an average image. Pictures were recorded
digitally in a 5126512 pixel format. A look-up table (glowover-
glowunder, Leica) ensured that the full dynamic range of the
photomultipliers was used. Before each measurement, a series of
sections was acquired through the vertical axis in order to choose
the equatorial section.
Anatomical and cellular distribution
Anatomical structures were identified under direct observation
using the atlas and nomenclature of Paxinos and Watson [68].
Light microscopic sections were examined using a Leica DMRB
brightfield microscope (objectives 1.66to 206).
Isolation of exocytosed material from stimulated SH-
SY5Y cells
SH-SY5Y cells were grown for 4 days in 24-well dishes (4610
5
cells per well) in DMEM with 10% fetal bovine serum (FBS, Sigma
Aldrich). Prior to the experiments, they were washed twice (5 min
each) with FBS-free DMEM at 37uC and incubated for 1 h in
FBS-free DMEM at 37uC. Cells were then incubated with or
without 100 mM nicotine in FBS-free DMEM for 24 h. The
culture medium was collected and tested for morphine using a
Morphine in Brain Cells
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below). Cadmium treatments (200 mM; Sigma Aldrich) were used
to assess whether a Ca
2+-dependent release mechanism exists.
Secretion efficiency was checked by Western blot analysis (see
below) using a validated antibody raised against the conserved C-
terminal part of chromogranin B (bovine CGB614-626 [69]), which
serves as a secretion marker [27].
Alkaloid and protein analysis
Prior to HPLC separation, Western blot analysis, or ELISA,
scraped cells or homogenized brain areas were sonicated at 4uC
(3610 sec) in water containing protease inhibitor cocktail (Roche
Diagnostics). The sonicates were centrifuged (30 min, 10000 g,
4uC), and the supernatant containing the intracellular material was
used for protein analysis after protein quantification [15].
Endogenous alkaloids present in the tissue or cell homogenates
were extracted as described in our previous study [15].
Purification of alkaloids by reverse phase HPLC
Deproteinized or untreated samples corresponding to 375610
6
cells, as well as alkaloid standards, were purified using an A ¨kta
purifier HPLC system (GE Healthcare Bioscience) as previously
described [15]. The gradients of acetonitrile (ACN) are indicated on
the chromatograms. Buffer A was 0.1% (v/v) in water, and buffer B
was 70% acetonitrile and 0.09% , trifluoroacetic acid in water.
Mass spectrometry
MS and MS-MS analyses were performed using electrospray
mass spectrometry (ES-MS) on a Q-TOF II (Bio-Tech) in positive
mode as previously described [15].
Gel electrophoresis and Western blot analysis
Proteins were separated on SDS-PAGE gradient gels (4%–12%
acrylamide; Criterion XT, BioRad) and electrotransferred onto
polyvinyldifluorene membranes (GE Healthcare Bioscience) [13].
UGT2B enzymes were detected with a goat polyclonal antibody
raised against the human UGT2B family (Santa Cruz Biotech-
nology, 65 kDa, dilution 1:1,000), and signal was developed using
HRP-conjugated anti-goat antisera (Santa Cruz Biotechnology,
dilution 1:50,000) [15]. Human hepatocyte extract (XenoTech)
and human recombinant UGT2B7 (Sigma Aldrich) were used as
positive controls. Chromogranin B (CGB) was detected using a
rabbit polyclonal antibody raised against the conserved C-terminal
part of chromogranin B (bovine CGB614-626 [69]), and the signal
was developed using HRP-conjugated anti-rabbit antisera (Sigma
Aldrich, dilution 1:400,000)
Morphine-specific ELISA
The morphine-specific ELISA kit from Immunalysis Corpora-
tion was used for the quantification of morphine present in culture
medium (n=6) and brain tissue extracts (n=5). The specificity of
the test for morphine was confirmed by testing different amounts
of M6G, M3G, and codeine (0–25 ng/ml, data not shown). For all
tests, morphine standards were diluted in the appropriate buffer.
Statistical analysis of the secretion experiments
In order to assess the effect of nicotine stimulation on SH-SY5Y
cells, morphine concentrations in the medium were subjected to
post hoc analysis using a Mann-Whitney test. Our analysis included
four different conditions: control, control+cadmium, nicotine,
nicotine+cadmium. Each value was the result of six independent
experiments (n=6). Statistical data analysis was performed using
MINITAB 13.20 (Minitab Inc.). Differences were considered to be
statistically significant when the probability value was ,0.01
(indicated by asterisks in the Figure).
Total RNA isolation and Reverse-Transcription
Polymerase Chain Reaction
Total RNA was extracted from SH-SY5Y cells using the
NucleoSpin RNA II extraction kit (Macherey-Nagel). RNA purity
was quantified by UV spectrophotometry at 260/280 nm.
Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
was performed with the One-Step RT-PCR kit (Qiagen) according
to the manufacturer’s protocol. Briefly, total RNA (100 ng) was
retro-transcribed into cDNA for 30 min at 50uC; after inactivation
of the transcriptase at 95uC for 15 min, PCR was performed for
35 cycles (1 min at 94uC, 1 min at the specific Tm, 1 min at 72uC)
followed by a final extension for 10 min at 72uC on a Mastercycler
personal (Eppendorf).
Forward and reverse primers specific to human MOR1 (59-39
ACCAACATCTACATTTTCAACCTT and 59-39 CAGTAC-
CAGGTTGGATGAGAG) were designed to amplify a 376-bp
fragment of the region common to all MOR1 splice variants
(OligoExplorer 1.2, Gene Link).
Human UGT2B7 forward and reverse primers (59-39 TCCAC-
GAGCATCTTCGAGA and 59-39 ATACTGGAAGCACATG-
CCC) were designed to amplify a 462-bp fragment specific to
UGT2B7, (OligoExplorer 1.2, Gene Link).
Amplification of GAPDH RNA was used as a positive control in
RT-PCR reactions. PCR products (one-fifth of the PCR reaction)
were loaded on an ethidium bromide-stained agarose gel (0.8%)
and visualized by UV illumination using the GeneSnap system
(Syngene).
Reactions were carried out using synthesized oligonucleotides
(6 mM final concentration) at a Tm of 51uC for MOR1 and
UGT2B7.
Patch-clamp experiments on SH-SY5Y cells
For patch-clamp recording, SH-SY5Y cells were maintained in
culture (DMEM+10% FCS and 50 U/ml penicillin, 50 mg/ml
streptomycin) at low density (about 2610
4 cells/ml) in 35 mm dishes
and subjected to recording experiments 3–8 days after plating.
M6G-inducedresponsesweremeasuredeitherinthecell-attachedor
whole-cell configuration of the patch-clamp technique [70] using an
Axopatch-B200 amplifier (Axon Instruments). For whole-cell
recording, the recording pipette had a 2–4 MV resistance when
filled with recording solution (131 mM K-gluconate, 10 mM
HEPES, 5.5 mM EGTA, 1 mM CaCl2, 2 mM MgCl2,3 m M
NaCl 5 mM KCl, 0.1 mM ATP, and 0.1 mM GTP). Isolated SH-
SY5Y cells were selected and recorded under continuous perfusion
with control medium (132 mM NaCl, 2 mM KCl, 1 mM CaCl2,
2m MM g C l 2, 1 mM Na-Gluconate, 10 mM HEPES and 10 mM
D-glucose). The pH of the pipette and bath medium was adjusted to
7.2 with KOH and 7.4 with NaOH, respectively. For cell-attached
recordings, the pipette was filled with bath medium. Voltage
command and current trace digitization were achieved using the
Digidata 1322A card interface (Axon Instruments) and Pclamp
software (Axon instrument). Current traces were low-pass filtered at
2 kHz before digitization at 5 kHz.
Drugs were diluted to the desired concentrations in the bath
medium and applied to the recorded cell through a multi-barrel
perfusion system (RCS-160 rapid solution exchanger, Bio-Logic).
Each barrel had a 1 mm inner diameter, and the selected
perfusion tube was placed about 50 mm from the recorded cell.
Drug application began when the selected tube was positioned in
front of the cell. Naloxone antagonist was purchased from Sigma
Aldrich.
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